TECENTRIQ® is NOW FDA APPROVED for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving TECENTRIQ.¹

To learn more, please visit TECENTRIQ.com

### IMPORTANT SAFETY INFORMATION

Serious and sometimes fatal adverse reactions occurred with TECENTRIQ treatment. Warnings and precautions include immune-related serious adverse reactions, including pneumonitis, hepatitis, colitis, endocrinopathies, and other immune-related adverse events. Other warnings and precautions include infection, infusion-related reactions, and embryo-fetal toxicity.

Please see additional Important Safety Information on following page and in accompanying full Prescribing Information.
DISTRIBUTION AND FULFILLMENT INFORMATION

• TECENTRIQ is available through authorized specialty distributors and wholesalers via the TECENTRIQ distribution network
• For additional network information, please contact Genentech BioOncology® Access Solutions by calling 1-888-249-4918 or by visiting www.genentech-access.com/tecentriq/hcp

PATIENT ACCESS INFORMATION

• Genentech BioOncology Access Solutions offers a full range of access and reimbursement support for your patients and practice to minimize delays in therapy and understand patient coverage and out-of-pocket costs
• For information on distribution and patient access support, please contact Genentech BioOncology Access Solutions for TECENTRIQ by calling 1-888-249-4918 or by visiting www.genentech-access.com/tecentriq/hcp

For additional information, please contact your Genentech representative.

IMPORTANT SAFETY INFORMATION

Serious Adverse Reactions
Please refer to the full Prescribing Information for important dose management information specific to adverse reactions.

• Immune-related pneumonitis. Immune-mediated pneumonitis or interstitial lung disease, including fatal cases, occurred. Permanently discontinue TECENTRIQ for Grade 3 or 4 pneumonitis
• Immune-related hepatitis. Immune-mediated hepatitis, including a fatal case in urothelial carcinoma (UC), and liver test abnormalities occurred. Permanently discontinue TECENTRIQ for Grade 3 or 4 immune-mediated hepatitis
• Immune-related colitis. Immune-mediated colitis or diarrhea, including a fatal case of diarrhea-associated renal failure in UC, occurred. Permanently discontinue TECENTRIQ for Grade 4 diarrhea or colitis
• Immune-related endocrinopathies. Immune-related thyroid disorders, adrenal insufficiency, hypophysitis, and type 1 diabetes mellitus, including diabetic ketoacidosis, have occurred. Permanently discontinue TECENTRIQ for Grade 4 hypophysitis
• Other immune-related adverse reactions. Meningoencephalitis, myasthenic syndrome/myasthenia gravis, Guillain-Barré syndrome, ocular inflammatory toxicity, and pancreatitis, including increases in serum amylase and lipase levels, have occurred. Permanently discontinue TECENTRIQ for any grade of meningitis or encephalitis, or any grade of myasthenic syndrome/myasthenia gravis or Guillain-Barré syndrome. Permanently discontinue TECENTRIQ for Grade 4 or any grade of recurrent pancreatitis
• Infection. Severe infections, including fatal cases, occurred. Sepsis, herpes encephalitis, and mycobacterial infection leading to retroperitoneal hemorrhage have been observed
• Infusion-related reactions. Severe infusion reactions have occurred. Permanently discontinue TECENTRIQ in patients with Grade 3 or 4 infusion reactions
• Embryo-fetal toxicity. TECENTRIQ can cause fetal harm in pregnant women. Advise patients of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TECENTRIQ and for at least 5 months after the last dose
• Advise female patients not to breastfeed while taking TECENTRIQ and for at least 5 months after the last dose

Most Common Adverse Reactions
The most common adverse reactions (rate ≥20%) included fatigue (46%), decreased appetite (35%), dyspnea (32%), cough (30%), nausea (22%), musculoskeletal pain (22%), and constipation (20%).

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see accompanying full Prescribing Information for additional Important Safety Information.